Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568869 | 1.00 | L3MBTL1 (0.62) | L3MBTL1HPGDKDM4ETSHRRECQL | |
| SCHEMBL10720509 | 0.88 | L3MBTL1 (0.71) | L3MBTL1HPGDKDM4ETSHRRECQL | |
| SCHEMBL1877596 | 0.85 | KDM4E (0.68) | L3MBTL1HPGDKDM4ECA12CA1 | |
| SCHEMBL15271489 | 0.85 | CA12 (0.64) | L3MBTL1HPGDKDM4ECA12CA1 | |
| SCHEMBL3227656 | 0.84 | MEN1 (0.63) | L3MBTL1HPGDKDM4ETSHRRECQL | |
| Hydrochloric Acid SCHEMBL7128756 | 0.83 | KDM4E (0.66) | L3MBTL1HPGDKDM4ECA12CA1 | |
| SCHEMBL28294867 | 0.83 | HPGD (0.71) | L3MBTL1HPGDKDM4ETSHRRECQL | |
| SCHEMBL7090972 | 0.83 | HPGD (0.66) | L3MBTL1HPGDKDM4ECA12CA1 | |
| SCHEMBL15695610 | 0.83 | KDM4E (0.65) | L3MBTL1HPGDKDM4ETSHRPKM | |
| SCHEMBL4831334 | 0.83 | KMO (0.72) | L3MBTL1HPGDKDM4ETSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452952-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2024-10-30 | — | — | EP | claimed |
| CN-118451062-A | Preparation and use of quinazolinediones | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-08-06 | — | — | CN | claimed |
| WO-2023119320-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-06-29 | — | — | WO | claimed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| EP-2188289-A2 | (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | Lexicon Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | claimed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | claimed |
| WO-2009021169-A2 | (7H-PYRR0L0 [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | LEXICON PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-05-19 | — | — | US | disclosed |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | disclosed |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | NOVARTIS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4452952-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2024-10-30 | — | — | EP | disclosed |
| CN-118451062-A | Preparation and use of quinazolinediones | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-08-06 | — | — | CN | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | MDH2, MDH1, ME2 | L3MBTL1 2962/4885HPGD 202/4885KDM4E 820/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | L3MBTL1 2077/4885HPGD 1383/4885KDM4E 2852/4885 |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | ATG7, GOT1, ULK1 | L3MBTL1 930/4885HPGD 2403/4885KDM4E 402/4885 |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | EZH2, BMI1, SUZ12 | L3MBTL1 2973/4885HPGD 1404/4885KDM4E 48/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | L3MBTL1 3525/4885HPGD 44/4885KDM4E 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.